Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Enliven Therapeutics, Inc. (ELVN : NSDQ)

• Company Description    Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO. Number of Employees: 62

• Price / Volume Information    Yesterday's Closing Price: $15.40 Daily Weekly Monthly 20 Day Moving Average: 757,427 shares Shares Outstanding: 59.35 (millions) Market Capitalization: $913.95 (millions) Beta: 0.41 52 Week High: $25.37 52 Week Low: $13.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.04% -27.92% 12 Week -27.67% -28.83% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6200 Lookout Road - Boulder,CO 80301 USA ph: 720-647-8519 fax: - ir@enliventherapeutics.com http://www.enliventherapeutics.com

• General Corporate Information    Officers Samuel Kintz - President; Director; and Chief Executive Officer Richard Heyman - Chairman of the Board Benjamin Hohl - Chief Financial Officer Rahul Ballal - Director Jacob Bauer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 29337E102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 59.35 Most Recent Split Date: 2.00 (0.25:1) Beta: 0.41 Market Capitalization: $913.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.97 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.92 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: 34.69% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -24.88 06/30/25 - -29.15 ROA 12/31/25 - - 09/30/25 - -23.96 06/30/25 - -27.88 Current Ratio 12/31/25 - - 09/30/25 - 32.95 06/30/25 - 32.58 Quick Ratio 12/31/25 - - 09/30/25 - 32.95 06/30/25 - 32.58 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 8.04 06/30/25 - 8.25 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©